麻豆传媒

Oncology/Hematology >

Leukemia

News, opinions and meeting coverage in oncology/hematology.

IGHV-Unmutated CLL: Gene Signature May Predict Outcomes After First-Line FCR

Prognostic tool may predict who is likely to achieve a relatively long remission

Fludarabine, cyclophosphamide, and rituximab over a chronic lymphocytic leukemia (CLL) blood smear under light microscopy

FCR Still an Option in IGHV-Unmutated CLL?

Gene signature identifies lower-risk group with greater chemoimmunotherapy benefit

The bottle and packaging of Imbruvica over an electrocardiogram

Ibrutinib's Cardiotoxicity Comes Into Focus

Study identifies new cardiac events linked to so-called targeted therapy

A photo of the Georgia World Conference Center with the acronym AACR overlaid.

Overall Survival Data in for Gilteritinib as AML Salvage Tx

FLT3 Inhibitor tops chemotherapy in randomized trial

A young pensive female cancer patient hugging a teddy bear.

Transplant No Help in Hypodiploid ALL

Similar 5-year outcomes with or without HSCT, regardless of MRD status

2019 SIR Meeting Convention in Austin, Texas

Are Patients Better Off With Image-Guided Bone Marrow Biopsy?

Prospect of sedation has some going to interventional radiology

Increased Risk of Chemo-Associated AML for Nearly All Solid Cancers

Extended beyond 5 years for most types with greater risk seen in young patients

Higher Risk of Shingles Seen in Patients With Certain Cancers

Vaccine development may help with prevention of herpes zoster in this population

ASH Poster Rounds: Obesity Impacts CLL Survival in Women

Plus: New risk model predicts CLL survival; novel BTK inhibitor works after ibrutinib

Chemo-Free Tx Tops Best Option in Younger CLL Patients

Improved overall survival and safety with ibrutinib-based therapy

Add-On Drugs Could Boost Efficacy, Tolerability of CAR T-Cell Therapies

Studies test addition of targeted agents, immunotherapy

CAR T-Cell Responses Prove Durable in ALL, DLBCL

Two studies demonstrate long-term control in relapsed/refractory disease

Ibrutinib Alone Wins in Older CLL Patients

Adding rituximab offered no added benefit

Sneak Peek at Practice-Changing Research From ASH 2018

"Big trials, big results," plus sickle cell disease and CAR T-cell therapies

Levaquin With Chemo Reduces Bacteremia in Pediatric AML/ALL

But no advantage seen among those undergoing transplant

FDA Warns Against Long-Term Zmax Use in Certain Cancer Patients

Heightened risk of relapse, death seen in study of stem cell transplant recipients

Decades Later, Mortality for Childhood Transplant Recipients Remains High

Elevated risk requires closer follow-up care

Nothing Good for Older Lung Cancer Patients From Add-On Cisplatin

Two trials show no survival benefit and more toxicity

Second Transplant vs Donor Lymphocyte Infusion in Relapsed AML

Both options viable, benefit more clear in certain groups

FLT3-ITD Inhibitor Improves Survival in Relapsed AML

More quizartinib-treated patients went on to stem cell transplant

Lymphoma Risk with JAK Inhibitors for MPNs

Preexisting aberrant B-cell clone implicated

Ivosidenib Induces Deep Remissions in IDH1-Mutant AML

On strength of phase I data, drug appears headed for FDA approval

Algorithm Helps Manage Fever

Pediatric cancer patients with non-neutropenic fever could benefit

Make the Diagnosis: What鈥檚 to Blame for his Rash and Paresthesia?

Case Findings: A 52-year-old man who was undergoing chemotherapy for leukemia went to the ED 5 days after receiving cytarabine. He complained of a rapid onset of erythematous lesions on his palms and soles accompanied by tingling and burning sensations. Can you diagnose the patient?

New Clues to CAR T-Cell Failure

Chemo effects, T cell energy sources

Gladiator Blood and Liquid Gold: Good for What Ails You?

A new book by Lydia Kang, MD, reviews the most dubious cures in history

Mixed Results with Regimens for Older AML Patients

Positive data with venetoclax, liposomal cytarabine-daunorubicin

Vince DeVita鈥檚 Oncology Opus

Medicine and music share center stage in storied career

MSK Cancer Alliance: Mainly About Medicine

Bi-directional relationship strengthens regional cancer care

Bangladesh-Boston Collaborate on ASCT Center

Two dozen patients undergo successful stem cell transplant in Dhaka

Can Patients With Stable CML Stop Drug Therapy?

Studies examine TKI cessation and dose reduction

Survival Boost With Liposomal Tx in Older AML Patients

Agent may also provide a bridge to successful transplant

CML Patients Still Benefit from Transplant

Also at SOHO: Ponatinib proves mettle in pretreated CML

Hypomethylating Agents Useful in Low-Risk MDS

Objective responses in a majority of patients

Gross Anatomy: When Orchids Attack!

Also, a mysterious case of sandpapery skin

Antitibiotic-Chemo Combo Cuts Infection Risk in AML

Incidence of Streptococcus viridans more than halved with prophylaxis.

Part 2: Oncologists Weigh In on PBS Cancer Documentary

Six specialists share their impressions of Ken Burns' cancer opus.

Jakafi Requires Careful Dosing Early: Experts

NEW YORK -- The JAK inhibitor can make a big difference for myelofibrosis patients, but must be monitored.

OncoBlog: Driving the CAR to a Cancer Cure?

Is immunotherapy with chimeric antigen receptor (CAR)-directed T cells the "next big thing" in oncology? Presentations and discussion at a recent conference suggest the technology has considerable promise -- but will it qualify as a breakthrough? OncoBlog is a blog by the Medpage Today staff for readers with an interest in oncology. This post comes from Charles Bankhead.

Gene Therapy Works in SCID With No Risk of Leukemia

NEW ORLEANS -- Genetic therapy appeared to restore the immune system of patients with X-linked severe combined immunodeficiency (SCID), but without leading to leukemia as a side effect, researchers reported here.

5